Volume 26, Number 8—August 2020
Pulmonary Embolism and Increased Levels of D-Dimer in Patients with Coronavirus Disease
We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of D-dimer levels and were given a diagnosis of pulmonary embolisms.
Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has been extensively reported since the outbreak in Wuhan, China, and can progress to involve major respiratory complications (1). Patients commonly have fever, cough, abdominal pain, and diarrhea.
During the second week of illness, decompensation occurs in some patients, possibly driven by the cytokine storm associated with increased levels of interleukin-6. We report 3 case-patients with COVID-19 who were improving after successful treatment during the critical period but showed development of pulmonary emboli (PEs) despite deep vein thrombosis (DVT) prophylaxis.
Three patients admitted to Northwell Plainview Hospital (Plainview, NY, USA) showed positive results for COVID-19 and had acute hypoxic respiratory failure secondary to COVID-19. All 3 patients received azithromycin and hydroxychloroquine, but their conditions continued to progress to more severe respiratory failure. During what was assumed to be the cytokine storm phase, on the basis of laboratory parameters and an increasing requirement for oxygen, the patients received intravenous steroids (solumedrol, 1–2 mg/kg/d for 5–8 d) and the interleukin-6 receptor antagonist tocilizumab (400 mg intravenously). Patients showed improvement and did not require intubation but later showed development of persistent hypoxemia with increases in levels of D-dimer. Computed tomography angiograms (CTAs) confirmed bilateral PEs, and the patients required supplemental oxygen (Table).
Case-patient 1, a 52-year-old male former smoker with a history of asthma, came to our hospital 12 days after symptom onset. At admission, he reported chest tightness, difficulty breathing, and was afebrile. His respiratory rate was 34 breaths/min, heart rate 87 beats/min, and blood pressure 117/67 mm Hg. The D-dimer level was 2,283 μg/mL at admission and increased to 9,698 μg/mL on hospital day 6. He had been receiving enoxaparin (40 mg/d subcutaneously) as venous thromboembolism (VT) prophylaxis. He had worsening hypotension, dyspnea on exertion, chest discomfort, and shortness of breath. CTA performed on symptom day 18 showed bilateral PEs. The patient was given enoxaparin (1 mg/kg subcutaneously 2×/d), transitioned to rivaroxaban, and discharged receiving supplemental oxygen.
Case-patient 2, a 60-year-old female nonsmoker with a history of chronic bronchitis, ovarian cancer postoophorectomy, and provoked DVT 18 years earlier, was admitted on day 8 of symptoms. At admission, she reported worsening cough, nausea, and loss of sense of smell. She was afebrile; her respiratory rate was 20 breaths/min, heart rate 106 beats/min, and blood pressure 145/68 mm Hg. The D-dimer level was 221 μg/mL at admission and 2,563 μg/mL on hospital day 10. She was given DVT prophylaxis (enoxaparin, 40 mg/d subcutaneously, increased to 2×/d on day 10 of illness). On day 18 of symptoms, she was persistently hypotoxic and had tachycardia and hypotension. CTA showed multiple bilateral segmental and subsegmental PEs with suggestion of cardiac strain. The patient was given rivaroxaban and discharged receiving supplemental oxygen.
Case-patient 3, a 68-year-old male nonsmoker with a history of hypertension, and type 2 diabetes mellitus, was admitted on day 14 of symptoms. At admission, he reported cough, difficulty breathing, and progressive weakness. He was afebrile; his respiratory rate was 22 breaths/min, heart rate 107 beats/min, and blood pressure 144/92 mm/Hg, and he showed hypotoxicity. The D-dimer level was 33,318 μg/mL at admission and 1,554 μg/mL on hospital day-7. He was given DVT prophylaxis (enoxaparin, 40 mg/d subcutaneously). On day 22 of symptoms, he showed development of hypotension, and his oxygen saturation was <90% with a 100% nonrebreather mask. This finding prompted a CTA, which showed bilateral PEs on hospital day 3. The patient was given enoxaparin (1 mg/kg subcutaneously 2×/d) and showed improvement.
PEs can occur after the cytokine storm in COVID-19 patients, despite DVT prophylaxis. After initial improvements, patients might continue to have high or increasing oxygen requirements because of development of thromboembolic disease. Previous studies showed that low levels of platelets, increased levels of D-dimer, and increasing levels of prothrombin in COVID-19 were associated with poor outcome, which might be explained by thromboembolic complications in patients with severe disease (2). Platelet counts remained within reference ranges for 2 of our patients and only decreased for 1 patient. Two patients had increases in D-dimer levels, and the third patient was admitted with a highly increased D-dimer level.
Autopsy reports from COVID-19 patients have shown microthrombi in lungs and in other organs with associated foci of hemorrhage (3,4). These findings suggest that severe endothelial dysfunction, driven by the cytokine storm and associated hypoxemia, leads to disseminated intravascular coagulation, causing thromboembolic complications. In these patients, other parameters, such as the neutrophil–lymphocyte ratio, and inflammatory markers, including ferritin, C-reactive protein, and lactate dehydrogenase, were returning to reference levels despite increased D-dimer levels and increasing oxygen requirements. Standard dose DVT prophylaxis did not prevent this complication. This hypercoagulability was a consumptive coagulopathy and was not caused by an inhibitor, such as an anticardiolipin antibody; treatment with direct factor Xa inhibitors would be appropriate.
Although certain underlying conditions might have influenced the coagulation process in these patients, the hypothesis that hypercoagulability is driven by endothelial dysfunction is plausible. These case studies support the earlier observation that anticoagulation is associated with a decrease in mortality rates for COVID-19 patients (5). Monitoring disseminated intravascular coagulation and measurement of platelet counts,D-dimer and fibrinogen levels, and trending International Society of Thrombosis and Haemostasis scores might be beneficial for early diagnosis of PE in patients with COVID-19.
Dr. Griffin is an instructor in clinical medicine and associate research scientist at Columbia University Medical Center, New York, NY. His primary research interests are HIV, stem cells, and malignancies.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;NEJMoa2002032.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. DOIPubMedGoogle Scholar
- Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;•••:
ehaa254. DOIPubMedGoogle Scholar
- Zuckier LS, Moadel RM, Haramati LB, Freeman L. Diagnostic evaluation of pulmonary embolism during the COVID-19 pandemic. J Nucl Med. 2020;pii:jnumed.120.245571.
- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;•••.
TableCite This Article
Original Publication Date: April 29, 2020
Table of Contents – Volume 26, Number 8—August 2020
|EID Search Options|
|Advanced Article Search – Search articles by author and/or keyword.|
|Articles by Country Search – Search articles by the topic country.|
|Article Type Search – Search articles by article type and issue.|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Daniel O. Griffin, Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, 701 W 168th St, HHSC 1310, New York, NY 10032-3784, USA